Herbst, R. S. Et Al. 2020. Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110. SWISS MEDICAL WEEKLY .

Herbst, R. S., De Marinis, F., Giaccone, G., Stahel, R., Reinmuth, N., Vergnenegre, A., ... Barrios, C. H.(2020). Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110. SWISS MEDICAL WEEKLY .

Herbst, R. Et Al. "Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110," SWISS MEDICAL WEEKLY , 2020

Herbst, R. S. Et Al. "Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110." SWISS MEDICAL WEEKLY , 2020

Herbst, R. S. Et Al. (2020) . "Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110." SWISS MEDICAL WEEKLY .

@article{article, author={R. S. Herbst Et Al. }, title={Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110}, journal={SWISS MEDICAL WEEKLY}, year=2020}